{"category": "ham", "to_address": "ip-health@lists.essential.org", "from_address": "ben.krohmal@keionline.org", "subject": "[Ip-health] Clinical trials as public goods", "body": "Many of you may be interested in the following article arguing for public\nfunding of clinical trials:\n\n\nThe Economists' Voice\nVol. 4 (2007) / Issue 1 /\nThe Case for Public Funding and Public Oversight of Clinical Trials\nAvailable at: http://www.bepress.com/ev/vol4/iss1/art3\n     Tracy R. Lewis, Duke University\n     Jerome H. Reichman, Duke University\n     Anthony D. So, Duke University\nAbstract\n     Clinical drug trials are public goods and should be publicly\nfunded to avoid undersupply, the suppression of adverse results and\nother problems, according to Tracy R. Lewis, Jerome H. Reichman and\nAnthony D. So.\nRecommended Citation\n\n_______________________________________________\nIp-health mailing list\nIp-health@lists.essential.org\nhttp://lists.essential.org/mailman/listinfo/ip-health\n\n"}